(Q40517955)

English

Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately

scientific article published on January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Saenger R

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Maechler G

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Potreck M

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Zepp F

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Knuf M

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Habermehl P

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Schuerman L

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1135-1143

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Development and clinical testing of multivalent vaccines based on a diphtheria–tetanus–acellular pertussis vaccine: difficulties encountered and lessons learned

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Systematic review of the effects of pertussis vaccines in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Prevention of poliomyelitis: recommendations for use of only inactivated poliovirus vaccine for routine immunization. Committee on Infectious Diseases. American Academy of Pediatrics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Hepatitis B: vaccination programmes in Europe--an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Childhood immunisation in the European Union. Confederation of European Specialists in Paediatrics (CESP)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Pneumococcal conjugate vaccines in Europe, Berlin, Germany, 23-25 August 2000. Report of a European advisory board meeting.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Vaccine prevention of meningococcal disease, coming soon?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

DTPa-HBV-IPV/Hib vaccine (Infanrix hexa).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Antibody responses and reactions to the whole cell pertussis component of a combined diphtheria/tetanus/pertussis vaccine given at school entry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Safety of combination vaccines: perception versus reality

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.030

7 January 2021

Identifiers

10.1016/J.VACCINE.2004.08.030

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40517955&oldid=1899827054"